Citius Pharmaceuticals, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Leonard Mazur (CEO/Chairman) and Jaime Bartushak (CFO) certified the Q2 2026 Form 10-Q as of August 14, 2026, attesting that financial statements fairly present the company's condition and results, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud disclosures were noted in the certifications.
Why this rating
Boilerplate SOX certification with no new disclosures. Standard quarterly filing requirement; no operational or financial changes communicated.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.